{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:37:10Z","timestamp":1780393030348,"version":"3.54.1"},"reference-count":33,"publisher":"Korean Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2020,4,15]]},"abstract":"<jats:p>PurposeThe treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30\u2013expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit.Materials and MethodsThis phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30\u2013expressing NHL, with BV administered intravenously at 1.8 mg\/kg every 3 weeks. The primary endpoint was &gt; 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as \u2265 30% tumor cells positive for CD30 by immunohistochemistry.ResultsHigh-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16\/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a &lt;i&gt;post-hoc&lt;\/i&gt; analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5\/9) than MUM1-positive patients (13.3%, 2\/15).ConclusionBV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.<\/jats:p>","DOI":"10.4143\/crt.2019.198","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T01:44:28Z","timestamp":1565660668000},"page":"374-387","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30\u2013Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial"],"prefix":"10.4143","volume":"52","author":[{"given":"Seok Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hyeh","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Ick","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weon Seo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3787"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764258"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-461848"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126615"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1309\/V561QTM6854W4WAV"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-890"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M608817200"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5501\/wjv.v3.i4.22"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.974048"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0212-9"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578575"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nature07064"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1845"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-768234"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0036"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.752.752"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110403"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17358"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.494"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5045\/br.2017.52.4.243"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1179277"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2019-198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2019.198","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2019-198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T01:15:39Z","timestamp":1586740539000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2019.198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2019.198","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"2019-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-13","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}